In Brief: Saliva Diagnostic Systems v. Home Access Health
This article was originally published in The Gray Sheet
Saliva Diagnostic Systems v. Home Access Health: Firms resolve their legal differences via renegotiated contract under which SDS has agreed to license its Omni-Sal saliva collection device to Home Access for use in Home Access HIV test kits for non-rapid testing, SDS announces. SDS retains rights to sell and license the Omni-Sal "to other companies for rapid testing, for non-HIV applications, and for HIV non-rapid testing other than for use in kits." The two firms originally entered into a licensing agreement for the Omni-Sal technology in March 1995, but SDS filed suit in January requesting the court clarify the rights negotiated under the contracts; Home Access filed a counterclaim in June seeking damages of more than $3 mil. for SDS' attempt to cancel the agreement ("The Gray Sheet" June 17, In Brief)...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.